EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications
-
- Claire Schwab
- Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom;
-
- Sarra L. Ryan
- Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom;
-
- Lucy Chilton
- Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom;
-
- Alannah Elliott
- Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom;
-
- James Murray
- Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom;
-
- Stacey Richardson
- Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom;
-
- Christopher Wragg
- Bristol Genetics Laboratory, Southmead Hospital, North Bristol National Health Service Trust, Bristol, United Kingdom;
-
- John Moppett
- Department of Paediatric Haematology and Oncology, Bristol Royal Hospital for Children, Bristol, United Kingdom;
-
- Michelle Cummins
- Department of Paediatric Haematology and Oncology, Bristol Royal Hospital for Children, Bristol, United Kingdom;
-
- Oliver Tunstall
- Department of Paediatric Haematology and Oncology, Bristol Royal Hospital for Children, Bristol, United Kingdom;
-
- Catriona A. Parker
- Children’s Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, United Kingdom;
-
- Vaskar Saha
- Children’s Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, United Kingdom;
-
- Nicholas Goulden
- Department of Haematology, Great Ormond Street Hospital, London, United Kingdom; and
-
- Ajay Vora
- Department of Haematology, Sheffield Children’s Hospital, Sheffield, United Kingdom
-
- Anthony V. Moorman
- Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom;
-
- Christine J. Harrison
- Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom;
Description
<jats:title>Key Points</jats:title> <jats:p>EBF1-PDGFRB fusion accounts for ∼0.5% of B-cell precursor acute lymphoblastic leukemia and 2.7% of the B-other subtype. EBF1-PDGFRB-positive patients are MRD positive and are slow early responders who respond to imatinib.</jats:p>
Journal
-
- Blood
-
Blood 127 (18), 2214-2218, 2016-05-05
American Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1363951796214085632
-
- ISSN
- 15280020
- 00064971
-
- Data Source
-
- Crossref
